GlaxoSmithKline about to get the smackdown by the FDA on Avandia
If there is one bunch of corporations I hate more than health insurance corporations it is Big Pharma. Take GlaxoSmithKline. No, please seriously take them!
We have long recommended that consumers steer clear of the type 2 diabetes drug Avandia (rosiglitazone) because it can increase the risk of heart failure and could possibly trigger heart attacks. Beginning today, the medication faces what could be its final trial, as a committee of experts convened by the Food and Drug Administration will consider whether the drug’s safety problems are severe enough to warrant increased restriction of its use or removal from the market altogether.
The evidence against Avandia has continued to mount over the last several months. The two most recent studies found that Avandia is linked to an increased risk of heart attacks, strokes and death. And, an internal analysis conducted by FDA officials that was released in February concluded the drug causes heart attacks and deaths and should be pulled from the market.
Related posts:
